Article
ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of biological effects.
All News
Peter Nash
Tweet
Autoimmune Disease Outcomes of Women with Breast Implants: A Population-Based Study https://t.co/Z6R8zRezfN #breastimplants #IMID an old chestnut
Meral K. El Ramahi, MD
Tweet
Reducing Immunogenicity of Pegloticase (RECIPE) w/ concomitant use of MMF in pts w/ refractory gout is a phase II double blind RCT that shows sustained serum urate lowering effect in addition to decrease in monthly rate of flares. #ACRbest #Abst0952 @RheumNow Practice changing? https://t.co/Z7GwCXZftE
Danny Soulsby
Tweet
Next up! #Autoinflammatory diseases: mechanisms and management. First: CRMO & SAPHO with Dr. Polly Ferguson
Highlights:
📍The *many* names of CRMO/CNO
📍Clinical features
📍Rx options (NSAIDs, bisphosphonates, TNFi)
📍Role of innate immunity in etiology
#ACRambassador https://t.co/qP3IySJKGC
ARD & RMD Open
Tweet
Genotype analysis define new illnesses such as VEXAS.
”Somatic mutation may account for a significant fraction of adult-onset inflammatory disease” says Dr. Dan Castner.
Science enthusiasm at 3S038. Autoinflammatory Diseases.
@petercgrayson #ACR20 <TK https://t.co/gyTxF8NWtO
E. Sloan
Tweet
Fascinating and engaging talk by Dr. Kastner on the discovery of VEXAS using a genotype-first strategy. Definitely one to go back and watch if you missed it! #ACR20 https://t.co/D090V7HiG2
Richard Conway
Tweet
Dan Kastner giving an absolute tour de force of the discovery of VEXAS in autoinflammatory diseases: mechanisms and management session now. If you aren't listening, watch it back! #ACR20 @rheumnow https://t.co/zell5e2Brt
Bella Mehta
Tweet
Excellent session on #autoinflammatory syndromes #SAPHO syndrome -IL-1 role in disease pathogenesis and something that I ve not come across clinically #Majeed Syndrome @RheumNow #ACR20 #3S038 https://t.co/vnfjPD6Zx9
Richard Conway
Tweet
Dr Merriman presents on role of diet in gout. It is minor, especially compared to urate lowering therapy. Average attributable fraction approximately 10-fold greater for ULT than following healthy-eating guidelines. @rheumnow #ACR20 Abstr#951 https://t.co/1tftswOEJq
Richard Conway
Tweet
Dr Cai presents risk of CVD in gout in study 450,000 patients. Gout was independently associated with an increased risk of CVD events HR = 1.24 for women; 1.21 for men. @rheumnow #ACR20 Abstr#950 #ACRbest https://t.co/089aKtN5a7
Olga Petryna
Tweet
@RheumNow #ACR20 abs0710 early biologic therapy (BT) in JIA: Early BT=better outcome ( 81.8% on TNFi). BT start after 7,5mo from Dx correlates w/higher probability of active disease at 2 yrs (S=0,67 E=0,63). In active group at 2y 75% arthritis, 16,7% uveitis& 8,3% both. #ACRbest
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow and its Faculty.
Dr. John Cush
Tweet
Listen to part I of our #ACR20 Day 1 recap. Listen through the link below or find us on Apple podcasts.
https://t.co/W6EMQiF9Rf https://t.co/R1ieCFnIxz
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by Novartis. All content chosen by @RheumNow and its Faculty.
Richard Conway
Tweet
Dr Peral reports on intracellular crystal containing vacuoles in gout and CPP arthritis. Crystal containing vacuoles only seen in CPP arthritis. @rheumnow #ACR20 Abstr#666 https://t.co/ITQMXhjQt0
Richard Conway
Tweet
Dr Vargas-Santos reported on risk of gout with SGLT2-inhibitors using THIN database. Canagliflozin shown in prior RCT to reduce gout risk. Here dapagliflozin and empagliflozin showed even stronger effect @rheumnow #ACR20 Abstr#660 https://t.co/MTjByMmHo7
Richard Conway
Tweet
Dr Minalyan and colleagues report rates of gout flare following hospital admission of patients prescribed allopurinol. Gout flare 14 times more likely if allopurinol stopped or omitted. @rheumnow #ACR20 Abstr#688 https://t.co/x3eyX1PLFB
Richard Conway
Tweet
Dr McCormick reports sequential patterns of gout flare from the Boston Online Gout Study. Second attack most likely to affect ipsilateral same joint, and second most likely contralateral same joint. @rheumnow #ACR20 Abstr#672 https://t.co/2AAMvcOCk8
Dr. John Cush
Tweet
Get the highlights on the opening day of #ACR20. Listen in to faculty reports and overviews. Follow the link below or find us on Apple podcasts under RheumNow Podcast.
https://t.co/qDQzCAHsHi https://t.co/9nM19ZdHQQ
sheila
Tweet
DECT in #gout: color-coded lesions at MTP1 jt & patellar tendon exclusively pure MSU depositions. CCDL in gout: both pure MSU & calcium-containing depositios. @RheumNow #ACR20 Abs#0445 https://t.co/7zudk2muBR
